The Supply of Investigational Medicinal Product and Management of Study Materials for Decentralized Participants—Insights from the Trials@Home RADIAL Proof‐of‐Concept Trial
Authors:
- Megan HeathMHMegan Heath
- Amos J. de JongAJAmos J. de Jong
- Danny R. van WeelijDWDanny R. van Weelij
- Yvonne van RijswickYRYvonne van Rijswick
- Bart LagerwaardBLBart Lagerwaard
- Mira G. P. ZuidgeestMZMira G. P. Zuidgeest
- The Trials@Home ConsortiumTCThe Trials@Home Consortium
Open Access
- 24 September 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (5) , 1079-1089
Abstract
Decentralized clinical trials (DCTs), which move trial activities to participants’ homes or direct surroundings, offer potential advantages over conventional site‐based trials through reduced participant burden and improved accessibility. The direct‐to‐participant (DtP) delivery of investigational medicinal products (IMPs) and other study materials and collection of biological samples requires careful planning and execution to ensure participant safety and data integrity. Here, we report operational experiences from the RADIAL proof‐of‐concept trial, a three‐arm parallel‐group study conducted across six European countries comparing conventional, hybrid, and fully decentralized approaches in type 2 diabetes patients. The study implemented two DtP IMP models: clinical trial site‐to‐participant and central pharmacy‐to‐participant delivery, with comprehensive logistics tracking and temperature monitoring. In RADIAL, 68 DtP IMP shipments were executed with a 94% successful delivery rate. Four shipments (6%) failed due to participant unavailability, temperature excursions, defective monitoring equipment, or courier loss. The central pharmacy model demonstrated inventory savings compared with conventional site‐based distribution. Biological sample collection for HbA1c assessment was done through drop‐off, which proved more challenging in the remote arm. Key challenges related to DCT logistics as experienced in RADIAL included unclear importer/exporter responsibilities, regulatory divergence across countries, participant material management, and sample drop‐off reliability. DtP IMP delivery and biological sample collection are feasible in European DCTs but require enhanced planning, clear vendor responsibilities, and robust contingency procedures. Success depends on appropriate participant training, reliable courier services, temperature control systems, and accessible biological sample collection methods.Keywords
This publication has 31 references indexed in Scilit:
- Albuminuria Responses to Dapagliflozin in Patients With Type 2 DiabetesJAMA Network Open, 2025
- Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs PlaceboJAMA Network Open, 2024
- Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19JAMA, 2023
- Racial and Ethnic Inequities in US Oncology Clinical Trial Participation From 2017 to 2022JAMA Network Open, 2023
- Blood microsampling technologies: Innovations and applications in 2022Analytical Science Advances, 2023
- Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19JAMA, 2023
- Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19JAMA, 2022
- COVID‐19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European UnionClinical Pharmacology & Therapeutics, 2021
- Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering TherapiesJAMA Network Open, 2020
- Prevalence, Characteristics, and Publication of Discontinued Randomized TrialsJAMA, 2014